A new study found that men with a BRCA2 mutation and metastatic hormone-sensitive prostate cancer face poorer outcomes. BRCA2 carriers were also found to have a higher risk of progression to castration-resistant prostate cancer. These findings highlight the importance of evaluating germline mutations among prostate cancer patients.
Learn more by reading the full article at: https://bit.ly/4dMkwxs
Reference: Custodio-Cabello, et al. 2024;42(10):331.e13-331.e24. PMID: 38926076.